文献速递临床试验与 GCP医学教育与科研方法

非瓣膜性房颤中医药临床试验核心结局集与测量工具研究方案

Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol.
PubMed 文献 · Trials · 2018-10-05

针对中国日益增多的非瓣膜性房颤中医药临床试验,结局指标和测量工具异质性大、多未报告终点结局及安全性,难以进行Meta分析。本研究拟由多学科指导委员会主导,通过系统评价、患者访谈、德尔菲调查和共识会议等八个阶段制定核心结局集,并推荐相应测量工具。该核心结局集有望提高结局报告一致性、减少报告偏倚。

要点

  • 现有房颤核心结局集方法学有限,缺乏中国专家和患者视角。
  • 研究分八阶段:系统评价、患者访谈、证候调查、两轮德尔菲、共识会等。
  • 最终形成中医药治疗非瓣膜性房颤临床试验的核心结局集及测量工具推荐。

核心结论

  • 将制定非瓣膜性房颤中医药临床试验的核心结局集并推荐测量工具,以提高结局报告一致性、减少报告偏倚。

研究设计与样本

  • 研究由国家多学科指导委员会主导,包括八个阶段:系统评价、患者半结构化访谈、中医证候名称识别与数据集构建、横断面证候调查、两轮德尔菲调查、共识会议及测量工具推荐。

关键数值与推荐

  • 系统评价将识别非瓣膜性房颤临床试验中目前报告的结局和中医证候。
  • 患者半结构化访谈用于补充潜在结局。
  • 中医证候名称将从医疗记录中识别并构建数据集。
  • 通过横断面研究调查中医证候。
  • 开展两轮德尔菲调查,并召开共识会议制定核心结局集。

临床怎么用

  • 核心结局集可用于未来中医药治疗非瓣膜性房颤的临床试验设计与报告,促进研究间的可比性和Meta分析可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increasing number of clinical trials of traditional Chinese medicine are being conducted in the treatment of non-valvular atrial fibrillation (NVAF) in China. However, the heterogeneity of outcomes and outcome measurement instruments has produced little evidence for traditional Chinese medicine in treating NVAF because many trials cannot be included in a meta-analysis. The majority of the trials did not report endpoint outcomes, side effects or other important outcomes for patients, which makes it difficult to evaluate the efficacy and safety of traditional Chinese medicine. Therefore, it is important to develop a core outcome set (COS). Although there are two related COSs for clinical trials of atrial fibrillation, the methodology is limited, and the perspectives of Chinese experts and patients are unclear. Therefore, we will develop a COS and recommend outcome measurement instruments after finishing the COS, which can be used for clinical trials of traditional Chinese medicine in NVAF. METHODS/DESIGN: The method of the study will include eight stages led by a national multidisciplinary Steering Committee: (1) A systematic review will be developed to identify currently reported outcomes and traditional Chinese medicine syndromes in clinical trials of NVAF, (2) Semi-structured interviews of patients will be conducted to fill gaps in potential outcomes, (3) Traditional Chinese medicine syndrome names will be identified from medical records, (4) A dataset of traditional Chinese medicine syndrome names will be developed, (5) The investigation of traditional Chinese medicine syndromes will be conducted from cross-sectional study, (6) Two rounds of Delphi surveys will be carried out, (7) A consensus meeting will be conducted to develop a COS, and (8) Recommendations of outcome measurement instruments (OMIs), which should be used in the COS, will be developed. DISCUSSION: The COS will improve the consistency of outcome reporting and reduce the reporting bias in NVAF clinical trials of traditional Chinese medicine to improve the value of traditional Chinese medicine clinical trials. TRIAL REGISTRATION: This study is not a clinical trial, so it is registered in Core Outcome Measures in Effectiveness Trials Initiative (COMET). Registration number: 941 . Registered on 22 December 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Qiu R, Li M, Zhang X, et al. Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol. Trials. 2018. PMID: 30290840. doi:10.1186/s13063-018-2904-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。